Joel A G van Roon

TL;DR: The type I IFN signature negatively predicts the clinical response to rituximab treatment in patients with RA, which supports the notion that IFN signaling plays a role in the immunopathology of RA.

TL;DR: Findings indicate that upregulation of Fc gamma R expression in RA with IL-10 treatment may counteract the otherwise antiinflammatory effects of IL- 10 by potentiating immune complex mediated proinflammatory responses.

TL;DR: Plasma-induced NET release was increased in SLE and APS patients, with the highest NET release found in patients with SLE (±APS), and increased levels of anti-nuclear and anti-dsDNA autoantibodies were associated with increased NET release in Sle andAPS.

TL;DR: A plea is made for future extensive immune cell profiling by a systems medicine approach in order to better unravel the pathogenesis of APS to gain more insight in the role of the immune system in APS as well as having the potential to reveal biomarkers or novel therapeutic targets.

TL;DR: Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS.